UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarkers of bone health and osteoporosis risk

Proceedings of the Nutrition Society, 2008-05, Vol.67 (2), p.157-162

2008

Volltextzugriff (PDF)

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

Journal of clinical oncology, 2008-03, Vol.26 (7), p.1051-1058

2008

Volltextzugriff (PDF)

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

Journal of clinical oncology, 2010-02, Vol.28 (6), p.967-975

2010

Volltextzugriff (PDF)

Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover

The journal of clinical endocrinology and metabolism, 2011-11, Vol.96 (11), p.3367-3373

2011

Volltextzugriff (PDF)

Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)

Journal of bone and mineral research, 2006-08, Vol.21 (8), p.1215-1223

2006

Volltextzugriff (PDF)

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

Clinical cancer research, 2008-10, Vol.14 (19), p.6336-6342

2008

Volltextzugriff (PDF)

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

Journal of bone and mineral research, 2010-03, Vol.25 (3), p.463-471

2010

Volltextzugriff (PDF)

Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption

Bone (New York, N.Y.), 2004, Vol.34 (1), p.187-194

2004

Volltextzugriff (PDF)

Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis

Journal of bone and mineral research, 2007-11, Vol.22 (11), p.1656-1660

2007

Volltextzugriff (PDF)

Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women

European journal of cancer (1990), 2007-11, Vol.43 (17), p.2523-2531

2007

Volltextzugriff (PDF)

Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study

Bone (New York, N.Y.), 2012-04, Vol.50 (4), p.885-892

2012

Volltextzugriff (PDF)

Risk Factors for Vertebral and Nonvertebral Fracture Over 10 Years: A Population‐Based Study in Women

Journal of bone and mineral research, 2008-01, Vol.23 (1), p.75-85

2008

Volltextzugriff (PDF)

Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer

Clinical breast cancer, 2015-04, Vol.15 (2), p.117-127

2015

Volltextzugriff (PDF)

Absence of Marked Seasonal Change in Bone Turnover: A Longitudinal and Multicenter Cross‐Sectional Study

Journal of bone and mineral research, 2003-07, Vol.18 (7), p.1274-1281

2003

Volltextzugriff (PDF)

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours

Oncology reports, 2006-05, Vol.15 (5), p.1351-1357

2006

Volltextzugriff (PDF)

The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases

Bone (New York, N.Y.), 2010-03, Vol.46 (3), p.801-805

2010

Volltextzugriff (PDF)

Biomarkers of bone health and osteoporosis risk: Symposium on ‘Diet and bone health’

Proceedings of the Nutrition Society, 2008-05, Vol.67 (2), p.157-162

2008

Volltextzugriff (PDF)

Erratum: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

Journal of bone and mineral research, 2012-06, Vol.27 (6), p.1435-1435

2012

Volltextzugriff (PDF)

Bone markers and current laboratory assays

Cancer treatment reviews, 2006, Vol.32, p.7-14

2006

Volltextzugriff (PDF)

Biochemical markers of bone turnover and fracture prediction

The journal of the British Menopause Society, 2003-03, Vol.9 (1), p.10-16

2003

Volltextzugriff (PDF)

Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism

European journal of endocrinology, 2000-05, Vol.142 (5), p.451-459

2000

Volltextzugriff (PDF)

Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays

Clinical chemistry (Baltimore, Md.), 1995-02, Vol.41 (2), p.318-319

1995

Volltextzugriff (PDF)

Seasonal Variation Present and Biologically Significant?

Journal of bone and mineral research, 2004-01, Vol.19 (1), p.170-171

2004

Volltextzugriff (PDF)

Biochemical markers of bone turnover and fracture prediction

The journal of the British Menopause Society, 2003-03, Vol.9 (1), p.10-15

2003

Volltextzugriff (PDF)

Chapter 27 - Biochemical markers of bone turnover

Menopause, 2007, p.337-349

Third Edition, 2007

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Englisch
(73)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(38)
Humans
(37)
Female
(33)
Endocrinology & Metabolism
(22)
Biological And Medical Sciences
(20)
Middle Aged
(18)
Aged
(15)
Medical Sciences
(15)
Male
(14)
Adult
(10)
Fundamental And Applied Biological Sciences. Psychology
(10)
Biomarkers - Blood
(9)
Bone Remodeling - Drug Effects
(9)
Tumors
(9)
Oncology
(8)
Osteoporosis
(8)
Breast Neoplasms - Drug Therapy
(7)
Diseases Of The Osteoarticular System
(7)
Bone Density - Drug Effects
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Biomarkers of bone health and osteoporosis risk

Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230

Prevention of Aromatase Inhibitor–Induced Bone Loss Using Risedronate: The SABRE Trial

Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover

Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2‐Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230)

Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose phase I trial

Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption

Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis

Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women

Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study

Risk Factors for Vertebral and Nonvertebral Fracture Over 10 Years: A Population‐Based Study in Women

Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer

Absence of Marked Seasonal Change in Bone Turnover: A Longitudinal and Multicenter Cross‐Sectional Study

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours

The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases

Biomarkers of bone health and osteoporosis risk: Symposium on ‘Diet and bone health’

Erratum: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

Bone markers and current laboratory assays

Biochemical markers of bone turnover and fracture prediction

Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism

Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays

Seasonal Variation Present and Biologically Significant?

Biochemical markers of bone turnover and fracture prediction

Chapter 27 - Biochemical markers of bone turnover

Suchergebnisse filtern